Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4.

Saved in:
Bibliographic Details
Title: Sequential JAK inhibition enhances antitumor immunity after combined anti-PD-1 and anti-CTLA4.
Authors: Arias-Badia M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Chen P; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Lwin YM; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Srinath A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Lyu A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Fan Z; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Kwek SS; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Luong DN; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Setayesh A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Sakamoto M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Clark M; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Lea A; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Wolters RM; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA., Goodearl A; AbbVie Bioresearch Center, Worcester, Massachusetts, USA., Harding FA; AbbVie Redwood City, Redwood City, California, USA., Gorman JV; Research and Development, AbbVie, North Chicago, Illinois, USA., Ritacco W; AbbVie Bioresearch Center, Worcester, Massachusetts, USA., Fong L; Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
Source: JCI insight [JCI Insight] 2025 Feb 27; Vol. 10 (7). Date of Electronic Publication: 2025 Feb 27.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 101676073 Publication Model: Electronic Cited Medium: Internet ISSN: 2379-3708 (Electronic) Linking ISSN: 23793708 NLM ISO Abbreviation: JCI Insight Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2379-3708
DOI:10.1172/jci.insight.187921